Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sosei completes Phase I study of SO-1105
The clinical study was designed to evaluate the pharmacokinetics and safety of SO-1105 in healthy Japanese adults. Sosei Group CEO Shinichi Tamura said, "This is an important step
The clinical study was designed to evaluate the pharmacokinetics and safety of SO-1105 in healthy Japanese adults. Sosei Group CEO Shinichi Tamura said, "This is an important step
The new facility suitable for production of oncological injectable products will be built at the company’s premise at the Tainan Science Park. ScinoPharm president and CEO Jo Shen
In Japan, Somatuline is indicated for the treatment of growth hormone and IGF-I (somatomedin-C) hypersecretion and related symptoms in acromegaly and pituitary gigantism (when response to surgical therapies
The product, Ibandronate Sodium tablets (150mg), is the bioequivalent generic version of Boniva tablets. According to IMS Health, the Boniva brand and generic had US sales of approximately
The APF530 offered a comparable nausea control and patient satisfaction to palonosetron (Aloxi) over a five-day period with no statistically significant differences in the multicenter, randomized, observer-blind trial.
Tenelia (generic name: Teneligliptin hydrobromide hydrate), a DPP-4 inhibitor created by Mitsubishi Tanabe, is found effective in the treatment of type 2 diabetes mellitus when satisfactory improvement cannot
The patent protects the use of IL-17E to treat cancer, including solid tumors such as colon, breast, ovarian, pancreatic and lung cancers in addition to melanoma until 2026.
DM1, which is also known as Steinert disease and the most common form of muscular dystrophy in adults, is a genetic neuromuscular disease characterized by progressive muscle atrophy,
Based on the positive results from phase I, II studies in Japan and phase III studies in abroad, Astellas has applied for the market authorisation in Japan. Astellas
The acquisition value includes Amylin’s debt proceeds and a contractual payment to Eli Lilly & Company, which amounts to nearly $7bn. With the completion of Bristol-Myers Squibb’s acquisition